Sarclisa is the first anti-CD38 treatment approved in China for patients with newly diagnosed multiple myeloma ineligible for transplant Approval based on positive results from the IMROZ phase 3 study ...
The total number of shares and votes in Anoto as of 31 January 2025 amounts to 1,102,362,753. This information is published in accordance with Chapter 4, Section 9 of the Swedish Financial Instruments ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback